BSE · 543500
Evoq Remedies Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹14 Cr with net profit ₹0 Cr — a 0.62% net margin, versus 7.17% the period before.
Shareholding
As of 2026-03-31
- Promoter0.02%
- Public99.98%
1,655 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.49× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — IBC. Trading may carry price bands, periodic call auction or higher margins.
- Promoter holding fell 11.2 percentage points to 0.02% in the latest disclosure.
Peer comparison
Trading · ranked #1 of 666 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,93,459 Cr | 24.35 | 4.83 | 3.42% | 9.3% |
| Avenue Supermarts Limited | ₹2,50,959 Cr | 381.38 | 10.26 | 12.14% | 4.32% |
| Trent Ltd. | ₹1,60,247 Cr | 266.89 | 22.94 | 24.62% | 8.57% |
| FSN E-Commerce Ventures Ltd. | ₹93,790 Cr | 1212.96 | 65.21 | 13.87% | 1.99% |
| Vishal Mega Mart Limited | ₹50,703 Cr | 300.67 | 6.82 | 11.32% | 6.61% |
| Premier Energies Limited | ₹47,038 Cr | 102.19 | 10.91 | 35.05% | 19.3% |
| Aegis Logistics Limited | ₹45,019 Cr | 109.72 | 7.44 | 14.83% | 10.78% |
| Aditya Infotech Limited | ₹40,364 Cr | 238.34 | 21.5 | 19.61% | 8.72% |
| Redington Limited | ₹22,472 Cr | 57.38 | 2.21 | 14.67% | 1.25% |
| Honasa Consumer Limited | ₹14,620 Cr | 210.96 | 10.36 | 14.16% | 8.36% |
| Evoq Remedies Limited(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashEvoq Remedies Limited has a market capitalization of Rs 24 Cr. The company reported revenue of Rs 14.17 Cr and a net profit of Rs 0.0882 Cr in March 2025.
Positives
- +The company's debt-to-equity ratio is low at 0.06.
- +Promoter shareholding in the company has no pledges (0%).
Negatives
- −Promoter holding has significantly decreased from 73.5289% in March 2023 to 0.0158% in March 2026.
- −Revenue declined from Rs 26.4126 Cr in March 2023 to Rs 6.309 Cr in March 2024.
- −Net profit decreased from Rs 1.6193 Cr in March 2023 to Rs 0.0882 Cr in March 2025.
- −The company is currently under the IBC surveillance measure.
Financial performance
The company's revenue was Rs 14.17 Cr in March 2025. This follows a revenue of Rs 6.309 Cr in March 2024 and Rs 26.4126 Cr in March 2023. Net profit was Rs 0.0882 Cr in March 2025, compared to Rs 0.4524 Cr in March 2024 and Rs 1.6193 Cr in March 2023.
Profitability & returns
Evoq Remedies Limited recorded an EPS of Rs 0.04 in March 2025. Previous EPS figures were Rs 0.33 in March 2024 and Rs 1.19 in March 2023. EBITDA for March 2025 stood at Rs 0.1282 Cr.
Balance sheet
The company maintains a low debt-to-equity ratio of 0.06.
Ownership & pledges
As of March 31, 2026, promoter shareholding in Evoq Remedies Limited is 0.0158%, while public shareholding stands at 99.9842%. There is no promoter pledging reported (0%). The number of shareholders is 1655. Institutional holding is 0% for both DII and FII.
Regulatory & surveillance
Evoq Remedies Limited is currently under the IBC surveillance measure.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.